

Press Release

adivo strengthens manufacturing set-up ahead of initiation of first-in-animal studies and partners with FyoniBio GmbH

adivo's CEASAR-derived cancer immunotherapy shows favorable product characteristics during process development and initial manufacturing steps

Martinsried/ Munich, Germany, November 21, 2022 – adivo GmbH, a leader in discovering species-specific therapeutic antibodies for pets, today announced that the company has transitioned its most advanced proprietary therapeutic candidate into the final stages leading up to the initiation of first-in-animal studies. The cancer antibody program addresses a well-established immune-oncology pathway in dogs and has now shown favorable characteristics in the scale-up and manufacturing process, for which adivo has partnered with Berlin-based [FyoniBio GmbH](#), a CDO expert specialized in tailored cell line development. The cancer program is one of two proprietary assets progressing towards first-in-animal studies within the next 12 months, driving the transformation of adivo into a clinical-stage biopharmaceutical company in the companion animal therapeutics space.

“Advancing a product candidate from lab-scale manufacturing to providing trial-grade and later on commercial-grade material is a pressure test for any therapeutic project and a significant value inflection point. We thus designed our species-specific antibody libraries clearly with developability in mind and are pleased to see the first results confirming a favorable manufacturing behavior of our most advanced product candidate,” commented Dr. Philipp Baer, Chief Scientific Officer of adivo. “We are excited to work with FyoniBio, whom we have chosen for their extensive experience in biopharma development and their ability to provide tailor-made services for companies of various sizes and at different development stages.”

The adivo technology platforms allows de-novo identification of species-specific antibody panels to select drug candidates with optimal functionality, developability and low risk of immunogenicity. adivo has established CEASAR, the first fully canine phage display platform in the veterinary medicines market for selecting therapeutic candidates against a broad range of diseases. Powered by more than two decades of combined therapeutic antibody discovery expertise gained in human medicine, the adivo leadership team is ideally positioned to bring forth developable candidates with best-in-class drug properties and molecular profiles tailored to the targeted species.

About adivo

adivo is forging a new era for companion animal health. Our proprietary phage display antibody libraries deliver species-specific drugs for a growing market need. We apply our extensive drug discovery and protein engineering know-how to address cancer, chronic inflammatory diseases and other serious conditions in pets. Together with our partners, we create the best possible therapeutics for our beloved furry friends. For further information, please visit: www.adivo.vet.

About FyoniBio

FyoniBio's ISO-9001 certified services comprising stable cell line development, process development and in-depth analytical characterization, including bioassays and clinical sample monitoring under GCLP. FyoniBio's expertise builds on the long-standing experience of its scientists, who have developed various cell lines and processes for biopharmaceutical products that have entered late-stage clinical trials. FyoniBio's customized approaches enable rapid, high-titer cell line development in various mammalian host cell lines that meet individual product requirements. In addition to the CHOnamite® platform, FyoniBio also offers the human GEX® platform, which is particularly suited for recombinant proteins with complex glycan structures. All services are provided within the framework of our internal quality management system to ensure compliance with the international ISO standard and international GMP standards.

Contact

adivo

Dr. Kathrin Ladetzki-Baehs

Phone +49 89 58 8088 471

E-mail: info@adivo.vet

For media

Mario Brkulj

Valency Communications

Phone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu